Hinge Health
Hinge Health is a digital clinic for musculoskeletal care, using AI motion tracking, wearables, and virtual physical therapy.
Secondary Market Price
Secondary Market Price
How hingehealth.com Measures Up
To help you manage your hingehealth.com equity, Prospect has run the company through our machine learning model.
Prospect Rating
TBD
We are still gathering data to finalize our rating for hingehealth.com. Check back soon for our projection of the company's worth four years from now.
Exit Risk
TBD
We are still gathering data on hingehealth.com to train our machine learning model. Check back soon for our exit risk rating for hingehealth.com!
Funding Stage
Series E
As a Series E company, Hinge Health is well-established and has moved beyond the initial, riskier startup phases. For a potential employee, this often points to a more stable work environment with a proven business model.
Secondary Market Price Chart
The secondary market prices for hingehealth.com shown here are a limited preview. Create a free account to access real-time secondary market prices
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future hingehealth.com Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for hingehealth.com's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
Hinge Health operates as a digital health technology company focused on treating and preventing musculoskeletal (MSK) conditions such as chronic joint and muscle pain. The company provides its services primarily to self-insured employers and health plans through a platform that combines wearable sensors, AI-powered computer vision for exercise feedback, and access to a remote clinical care team of physical therapists, health coaches, and physicians. Founded in 2014 by Daniel Perez and Gabriel Mecklenburg, the San Francisco-based company grew through significant venture capital funding, including a $400 million Series E round in late 2021. Its expansion has been supported by key acquisitions, including the therapeutic device company Enso Relief in March 2021 and the computer vision firm wrnch in September 2021.
Looking forward, Hinge Health has transitioned from a private entity to a publicly traded company, launching its initial public offering on the New York Stock Exchange in May 2025 under the ticker symbol HNGE. The public offering followed a period of sustained growth and technological development, including announcements that its TrueMotion computer vision technology demonstrated high accuracy in joint angle tracking. The company continues to invest in its technology, with numerous pending patents related to AI-powered pose estimation and personalized exercise feedback. Its stated plans involve continuing to scale its healthcare delivery model, expanding partnerships with health plans and employers, and growing its services into international markets.
- Tiger Global
- Insight Partners
- Bessemer
- Coatue
- Atomico
- Alkeon
- Lead Edge
- Whale Rock Capital
- Co-Founder, CEO Daniel Perez
- Co-Founder, Gabriel Mecklenburg
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is hingehealth.com worth joining?
Deciding whether to join Hinge Health depends on your personal career goals and the company's growth trajectory, financial health, and market position. Platforms like Prospect can help you evaluate the potential value of an equity offer by providing data-driven insights similar to those used by venture capitalists.
What should I do with my hingehealth.com stock?
Managing your Hinge Health stock involves making strategic decisions about when to exercise options and how to plan for taxes to maximize your earnings. You can use specialized tools from services like Prospect to create customized equity strategies and model different financial scenarios.
Can you sell hingehealth.com stock?
As Hinge Health is a private company, its stock is not traded on a public exchange, but you may be able to sell shares during company-approved tender offers or on secondary markets. These sales are subject to company policies and can have significant tax consequences that require careful planning.
How can I find the value of my hingehealth.com stock?
The official value of your private stock is determined by the company's most recent 409A valuation, which is used for tax purposes. To understand its potential future worth, you can use platforms like Prospect, which provide independent projections based on fundraising data, growth metrics, and market trends.
What is hingehealth.com's equity worth?
The total worth of Hinge Health's equity is based on its valuation from its latest funding rounds and internal 409A assessments. Your personal equity's value depends on the number of shares you hold and their grant price, which can be analyzed with tools from Prospect to forecast potential outcomes.
What is hingehealth.com's stock ticker symbol?
Hinge Health does not have a stock ticker symbol because it is a private company and its shares are not traded on a public stock exchange. Ticker symbols are only assigned to companies once they complete an Initial Public Offering (IPO).
Can I buy or sell hingehealth.com stock?
Selling your Hinge Health stock is sometimes possible through company-organized tender offers or on secondary markets, though restrictions apply. Buying stock is generally limited to accredited investors participating in funding rounds or employees exercising their stock options.
What is the criteria to buy or invest in hingehealth.com stock?
Typically, the opportunity to invest in a private company like Hinge Health is restricted to employees receiving equity compensation or accredited investors participating in private funding rounds. General retail investors cannot purchase shares until the company goes public.
